Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death

Fig. 5

Curcumin reverses gefitinib resistance in NSCLC cells through induction of autophagic cell death and autophagy-mediated apoptosis. a-b H157 and H1299 cells were treated with gefitinib plus curcumin at indicated concentration for 48 h in the absence or presence of Baf A1 (10 nM) or 3-MA (5 mM), cell viability was detected by CCK-8 assay. c H157 and H1299 cells were treated with gefitinib (5 μM) plus curcumin (10 μM) for 48 h in the absence or presence of 3-MA (5 mM). Cleaved (Cl)-caspase-3 and Cl-PARP were determined by immunoblotting. d Flow cytometry was used to analyze sub-G1 population in H157 and H1299 cells after drug treatment (5 μM gefitinib plus 10 μM curcumin in combination with or without 5 mM 3-MA). e After transfection with siBeclin-1 or siATG7 or siControl, H157 cells were treated with gefitinib (5 μM) plus curcumin (10 μM) for 48 h, Cl-caspase-3 and Cl-PARP were determined by immunoblotting. Similar results were obtained from three independent experiments. Typical immunoblots were presented in the Figure. f The sub-G1 population was analyzed by flow cytometry in H157 and H1299 after transfection with siBeclin-1 or siATG7 or siControl . g H157 cells were treated with gefitinib (5 μM) plus curcumin (10 μM) in the presence and absence of Z-VAD-MFK, immunoblotting was used to detect apoptosis- and autophagy-related proteins. h H157 cells were treated with gefitinib plus curcumin at indicated concentration in the presence or absence of Z-VAD-MFK, cell viability was determined by CCK-8 assay

Back to article page